G2GBIO raises 170B KRW and signs Samsung Bioepis deal, but financial burden remains

Q1 2026 revenue 350M KRW (vs 78M in Q1 2025), operating loss -3.3B, net loss -5.5B. Losses continue.
Raised total 170B KRW via CB (95B) and convertible preferred shares (75B) in Feb-Mar 2026. Cash & equivalents 123.5B.
Net debt ratio surged to 46.9% (from 2.5% end-2025). Recognized 49.3B derivative liabilities.
Signed joint research and license-out deal with Samsung Bioepis & Episnex Lab for semaglutide-based obesity/diabetes therapy.
Alzheimer drug (GB-5001) completed Ph1 in Canada & Korea; post-op pain (GB-6002) Ph1 done; veterinary (GB-2006) Ph2 done.
Patent invalidation trial (InventiaLab) and Australian patent opposition ongoing. Self-reported securities registration violations, potential fines.

ADVERTISEMENT (250px+)